Metabolic Diseases  >>  MKC253  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MKC253 / MannKind
NCT00475371: A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males

Completed
1a
26
Europe
MKC253 Inhalation Powder
Mannkind Corporation
Diabetes Mellitus, Type 2, Healthy Males
06/07
 
NCT00642538 / 2007-003430-42: A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

Completed
1
20
Europe
MKC253 Inhalation Powder, Technosphere Inhalation Powder, subcutaneous injection
Mannkind Corporation
Diabetes Mellitus, Type 2
09/08
09/08

Download Options